Alexion valuation could choke any Roche bid
By Caroline Copley ZURICH (Reuters) - Buying Alexion Pharmaceuticals Inc would help Roche make a splash in the newly lucrative area of rare or so-called orphan diseases, but it could command a price that the Swiss drug maker is ultimately not willing to pay. Two people familiar with the matter have told Reuters that the Basel-based firm is seeking financing for a potential bid for Alexion, which specializes in the treatment of rare diseases. ...
Editors' Picks
http://www.fizzlive.com/member/329936/blog/view/457670/http://mediawiki.spsnome.cz/index.php/Do_You_Really_Want_Help_On_All_Natural_Weight_Loss_Pillshttp://etreningi.ru/index.php?do=/blog/20194/the-dirty-facts-on-effective-diet-pills/
No comments:
Post a Comment